ERBB2 and aneurysmal bone cyst: Although established evidence indicates that the antitumor effects of trastuzumab are at least in part mediated by immune system activation and ADCC, no clinical evidence exists to support the prognostic role of peripheral blood immune cell populations in HER2+ aBC patients treated with first line trastuzumab-pertuzumab-based combinations.